Smith Julie 4
4 · EXELIXIS, INC. · Filed Feb 28, 2025
Insider Transaction Report
Form 4
EXELIXIS, INC.EXEL
Smith Julie
Director
Transactions
- Exercise/Conversion
Common Stock
2025-02-27$19.77/sh+23,347$461,570→ 65,292 total - Exercise/Conversion
Option (right to buy)
2025-02-27−23,347→ 19,294 totalExercise: $19.77From: 2019-05-23Exp: 2026-05-22→ Common Stock (23,347 underlying) - Exercise/Conversion
Option (right to buy)
2025-02-28−19,294→ 0 totalExercise: $19.77From: 2019-05-23Exp: 2026-05-22→ Common Stock (19,294 underlying) - Exercise/Conversion
Common Stock
2025-02-27$20.50/sh+31,167$638,924→ 41,945 total - Sale
Common Stock
2025-02-27$38.13/sh−54,514$2,078,619→ 10,778 total - Exercise/Conversion
Common Stock
2025-02-28$19.77/sh+19,294$381,442→ 30,072 total - Sale
Common Stock
2025-02-28$37.62/sh−19,294$725,840→ 10,778 total - Exercise/Conversion
Option (right to buy)
2025-02-27−31,167→ 0 totalExercise: $20.50From: 2018-05-24Exp: 2025-05-23→ Common Stock (31,167 underlying)
Footnotes (4)
- [F1]Includes 10,015 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.
- [F2]Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $37.75 to $38.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
- [F3]The option, representing the right to purchase a total of 31,167 shares of Common Stock, became fully exercisable on May 24, 2018.
- [F4]The option, representing the right to purchase a total of 42,641 shares of Common Stock, became fully exercisable on May 23, 2019.